Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRV NASDAQ:CLYM NASDAQ:ELDN NASDAQ:NKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRVAcrivon Therapeutics$1.52-1.9%$1.36$1.05▼$10.00$48.76M1.663.36 million shs875,976 shsCLYMClimb Bio$2.25-6.3%$1.83$1.05▼$8.79$162.63M-0.05615,476 shs404,709 shsELDNEledon Pharmaceuticals$2.42-4.7%$3.01$2.38▼$5.54$152.10M-0.12642,976 shs677,478 shsNKTXNkarta$1.97-4.8%$2.08$1.31▼$5.94$147.02M0.76499,491 shs802,769 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRVAcrivon Therapeutics-4.91%+19.23%+24.00%+29.17%-83.68%CLYMClimb Bio+0.84%+3.00%+49.07%+90.48%+239,999,900.00%ELDNEledon Pharmaceuticals-1.93%-2.68%-4.51%-11.50%-0.78%NKTXNkarta+2.48%-2.82%+5.61%+11.29%-67.76%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRVAcrivon Therapeutics$1.52-1.9%$1.36$1.05▼$10.00$48.76M1.663.36 million shs875,976 shsCLYMClimb Bio$2.25-6.3%$1.83$1.05▼$8.79$162.63M-0.05615,476 shs404,709 shsELDNEledon Pharmaceuticals$2.42-4.7%$3.01$2.38▼$5.54$152.10M-0.12642,976 shs677,478 shsNKTXNkarta$1.97-4.8%$2.08$1.31▼$5.94$147.02M0.76499,491 shs802,769 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRVAcrivon Therapeutics-4.91%+19.23%+24.00%+29.17%-83.68%CLYMClimb Bio+0.84%+3.00%+49.07%+90.48%+239,999,900.00%ELDNEledon Pharmaceuticals-1.93%-2.68%-4.51%-11.50%-0.78%NKTXNkarta+2.48%-2.82%+5.61%+11.29%-67.76%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRVAcrivon Therapeutics 3.00Buy$15.50919.74% UpsideCLYMClimb Bio 3.33Buy$9.00300.00% UpsideELDNEledon Pharmaceuticals 2.75Moderate Buy$10.00313.22% UpsideNKTXNkarta 3.00Buy$13.60590.36% UpsideCurrent Analyst Ratings BreakdownLatest ACRV, ELDN, CLYM, and NKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/2/2025ELDNEledon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.008/18/2025ELDNEledon PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/15/2025CLYMClimb BioBaird R WSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/15/2025CLYMClimb BioRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$9.008/14/2025ACRVAcrivon TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$9.00 ➝ $8.008/14/2025NKTXNkartaStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$14.00 ➝ $12.008/13/2025NKTXNkartaNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.007/25/2025ELDNEledon PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.006/18/2025ELDNEledon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy$9.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRVAcrivon TherapeuticsN/AN/AN/AN/A$5.68 per shareN/ACLYMClimb BioN/AN/AN/AN/A$3.15 per shareN/AELDNEledon PharmaceuticalsN/AN/AN/AN/A$1.05 per shareN/ANKTXNkartaN/AN/AN/AN/A$5.78 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRVAcrivon Therapeutics-$80.56M-$2.25N/AN/AN/AN/A-50.78%-46.08%11/12/2025 (Estimated)CLYMClimb Bio-$73.90M-$0.70N/AN/AN/AN/A-23.10%-22.47%11/11/2025 (Estimated)ELDNEledon Pharmaceuticals-$36.18M-$1.17N/AN/AN/AN/A-92.51%-38.31%11/11/2025 (Estimated)NKTXNkarta-$108.79M-$1.48N/AN/AN/AN/A-27.74%-22.38%11/6/2025 (Estimated)Latest ACRV, ELDN, CLYM, and NKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ELDNEledon Pharmaceuticals-$0.23-$0.13+$0.10-$0.13N/AN/A8/13/2025Q2 2025ACRVAcrivon Therapeutics-$0.57-$0.55+$0.02-$0.55N/AN/A8/12/2025Q2 2025CLYMClimb Bio-$0.19-$0.13+$0.06-$0.13N/AN/A8/12/2025Q2 2025NKTXNkarta-$0.37-$0.31+$0.06-$0.31N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRVAcrivon TherapeuticsN/AN/AN/AN/AN/ACLYMClimb BioN/AN/AN/AN/AN/AELDNEledon PharmaceuticalsN/AN/AN/AN/AN/ANKTXNkartaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRVAcrivon TherapeuticsN/A10.3110.31CLYMClimb BioN/A14.0814.08ELDNEledon PharmaceuticalsN/A8.128.12NKTXNkartaN/A15.6715.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRVAcrivon Therapeutics71.62%CLYMClimb Bio69.76%ELDNEledon Pharmaceuticals56.77%NKTXNkarta80.54%Insider OwnershipCompanyInsider OwnershipACRVAcrivon Therapeutics11.90%CLYMClimb Bio0.80%ELDNEledon Pharmaceuticals12.30%NKTXNkarta8.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRVAcrivon Therapeutics5831.46 million27.71 millionNot OptionableCLYMClimb Bio967.76 million67.22 millionN/AELDNEledon Pharmaceuticals1059.88 million52.52 millionOptionableNKTXNkarta14071.03 million65.06 millionOptionableACRV, ELDN, CLYM, and NKTX HeadlinesRecent News About These CompaniesAlyeska Investment Group L.P. Grows Position in Nkarta, Inc. $NKTXSeptember 8, 2025 | marketbeat.comNuveen LLC Invests $258,000 in Nkarta, Inc. $NKTXSeptember 8, 2025 | marketbeat.comAWM Investment Company Inc. Increases Holdings in Nkarta, Inc. $NKTXSeptember 5, 2025 | marketbeat.comNkarta to Participate in a September Investor ConferenceSeptember 2, 2025 | globenewswire.comNkarta, Inc. (NASDAQ:NKTX) Given Average Recommendation of "Buy" by BrokeragesAugust 26, 2025 | marketbeat.comEquities Analysts Issue Forecasts for Nkarta Q3 EarningsAugust 17, 2025 | marketbeat.comEquities Analysts Set Expectations for Nkarta Q3 EarningsAugust 17, 2025 | marketbeat.comWall Street Zen Upgrades Nkarta (NASDAQ:NKTX) to "Hold"August 17, 2025 | marketbeat.comNkarta (NASDAQ:NKTX) Given New $12.00 Price Target at Stifel NicolausAugust 16, 2025 | marketbeat.comNkarta (NASDAQ:NKTX) Receives Buy Rating from Needham & Company LLCAugust 15, 2025 | marketbeat.comNkarta price target lowered to $12 from $14 at StifelAugust 15, 2025 | msn.comNkarta (NASDAQ:NKTX) Announces Earnings Results, Beats Estimates By $0.06 EPSAugust 14, 2025 | marketbeat.comNkarta, Inc.: Nkarta Reports Second Quarter 2025 Financial Results and Corporate HighlightsAugust 13, 2025 | finanznachrichten.deNkarta, Inc. Reports Q2 2025 Financial ResultsAugust 12, 2025 | tipranks.comNkarta Reports Second Quarter 2025 Financial Results and Corporate HighlightsAugust 12, 2025 | globenewswire.comNkarta to Participate in the H.C. Wainwright "HCW@Home" SeriesJuly 23, 2025 | tmcnet.comNkarta to Participate in the H.C. Wainwright “HCW@Home” SeriesJuly 23, 2025 | globenewswire.comNkarta: Holding Its Support Steady Ahead Of First Data Readouts In 2025July 22, 2025 | seekingalpha.comWill Nkarta (NASDAQ:NKTX) Spend Its Cash Wisely?June 27, 2025 | uk.finance.yahoo.comNkarta, Inc. (NKTX) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comNkarta CMO David Shook Steps Down, Shawn Rose To SucceedJune 7, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACRV, ELDN, CLYM, and NKTX Company DescriptionsAcrivon Therapeutics NASDAQ:ACRV$1.52 -0.03 (-1.94%) Closing price 04:00 PM EasternExtended Trading$1.51 -0.01 (-0.66%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.Climb Bio NASDAQ:CLYM$2.25 -0.15 (-6.25%) As of 04:00 PM EasternClimb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.Eledon Pharmaceuticals NASDAQ:ELDN$2.42 -0.12 (-4.72%) Closing price 04:00 PM EasternExtended Trading$2.50 +0.08 (+3.31%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Nkarta NASDAQ:NKTX$1.97 -0.10 (-4.83%) Closing price 04:00 PM EasternExtended Trading$2.00 +0.03 (+1.57%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
